Drug Profile
Research programme: virus-like particle vaccines - ARTES Biotechnology/Burnet Institute
Alternative Names: HepSeeVaxDelta3™METAVAX® vaccineLatest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator ARTES Biotechnology; Burnet Institute
- Class Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Hepatitis-C(Prevention) in Australia
- 28 Aug 2020 No recent reports of development identified for research development in Hepatitis-C(Prevention) in Germany
- 29 Jul 2016 Early research in Hepatitis C (Prevention) in Australia, Germany